Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ. 2012;344: e2986.

Article  PubMed  Google Scholar 

Foudah AI, Devi S, Alam A, Salkini MA, Ross SA. Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer’s disease in rats: mechanistic approach to prevent inflammation. Front Pharmacol. 2023;14:1115721.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konishi K, Hori K, Uchida H, Watanabe K, Tominaga I, Kimura M, et al. Adverse effects of anticholinergic activity on cognitive functions in Alzheimer’s disease. Psychogeriatrics. 2010;10(1):34–8.

Article  PubMed  Google Scholar 

Alzheimer’s Association. 2022 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2022;18.

Small G, Bullock R. Defining optimal treatment with cholinesterase inhibitors in Alzheimer’s disease. Alzheimers Dement. 2011;7(2):177–84.

Article  CAS  PubMed  Google Scholar 

Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120(5):388–97.

Article  CAS  PubMed  Google Scholar 

Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335–48.

Article  CAS  PubMed  Google Scholar 

Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J Roy Soc Med. 2000;93(9):457–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doraiswamy PM, Husain MM. Anticholinergic drugs and elderly people: a no brainer? Lancet Neurol. 2006;5(5):379–80.

Article  PubMed  Google Scholar 

Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.

CAS  PubMed  Google Scholar 

López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic drugs in geriatric psychopharmacology. Front Neurosci. 2019;13:1309.

Article  PubMed  PubMed Central  Google Scholar 

By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767.

Article  Google Scholar 

Naugler CT, Brymer C, Stolee P, Arcese ZA. Development and validation of an improving prescribing in the elderly tool. Can J Clin Pharmacol. 2000;7(2):103–7.

CAS  PubMed  Google Scholar 

Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.

Article  CAS  PubMed  Google Scholar 

Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–32.

Article  PubMed  PubMed Central  Google Scholar 

Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer’s disease. Molecules. 2022;27(6):1816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(4):458–61.

Article  PubMed  Google Scholar 

Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc. 2008;56(5):847–53.

Article  PubMed  PubMed Central  Google Scholar 

Hilmer SN, Mager DE, Simonsick EM, Cao Y, Ling SM, Windham BG, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.

Article  PubMed  Google Scholar 

Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508–13.

Article  PubMed  Google Scholar 

Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481–6.

Article  CAS  PubMed  Google Scholar 

Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.

Article  PubMed  PubMed Central  Google Scholar 

Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008. https://doi.org/10.2217/1745509X.4.3.311.

Article  Google Scholar 

Lozano-Ortega G, Johnston KM, Cheung A, Wagg A, Campbell NL, Dmochowski RR, et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87: 103885.

Article  CAS  PubMed  Google Scholar 

Hanlon JT, Boudreau RM, Roumani YF, Newman AB, Ruby CM, Wright RM, et al. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci. 2009;64(4):492–8.

Article  PubMed  Google Scholar 

Gray SL, LaCroix AZ, Blough D, Wagner EH, Koepsell TD, Buchner D. Is the use of benzodiazepines associated with incident disability? J Am Geriatr Soc. 2002;50(6):1012–8.

Article  PubMed  PubMed Central  Google Scholar 

Chatterjee S, Walker D, Kimura T, Aparasu RR. Prevalence and factors associated with cumulative anticholinergic burden among older long-stay nursing home residents with overactive bladder. Drugs Aging. 2021;38(4):311–26.

PubMed  PubMed Central  Google Scholar 

Szabo SM, Gooch K, Schermer C, Walker D, Lozano-Ortega G, Rogula B, et al. Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study. BMJ Open. 2019;9(5): e026391.

Article  PubMed  PubMed Central  Google Scholar 

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019;179(8):1084–93.

Article  PubMed  PubMed Central  Google Scholar 

Heath L, Gray SL, Boudreau DM, Thummel K, Edwards KL, Fullerton SM, et al. Cumulative antidepressant use and risk of dementia in a prospective cohort study. J Am Geriatr Soc. 2018;66(10):1948–55.

Article  PubMed  Google Scholar 

Lozano-Ortega G, Schermer CR, Walker DR, Szabo SM, Rogula B, Deighton AM, et al. Fall/fracture-related healthcare costs and their association with cumulative anticholinergic burden in people with overactive bladder. Pharmacoecon Open. 2021;5(1):45–55.

Article  PubMed  Google Scholar 

Gray SL, Dublin S, Yu O, Walker R, Anderson M, Hubbard RA, et al. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016;352: i90.

Article  PubMed  PubMed Central  Google Scholar 

Haddad YK, Kakara R, Marcum ZA. A comparative analysis of selective serotonin reuptake inhibitors and fall risk in older adults. J Am Geriatr Soc. 2022;70(5):1450–60.

Article  PubMed  PubMed Central  Google Scholar 

Williams A, Sera L, McPherson ML. Anticholinergic burden in hospice patients with dementia. Am J Hosp Palliat Care. 2019;36(3):222–7.

Article  PubMed  Google Scholar 

Mate KE, Kerr KP, Pond D, Williams EJ, Marley J, Disler P, et al. Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015;32(2):159–67.

Article  CAS  PubMed  Google Scholar 

Reppas-Rindlisbacher CE, Fischer HD, Fung K, Gill SS, Seitz D, Tannenbaum C, et al. Anticholinergic drug burden in persons with dementia taking a cholinesterase inhibitor: the effect of multiple physicians. J Am Geriatr Soc. 2016;64(3):492–500.

Article  PubMed  PubMed Central  Google Scholar 

Ah YM, Suh Y, Jun K, Hwang S, Lee JY. Effect of anticholinergic burden on treatment modification, delirium and mortality in newly diagnosed dementia patients starting a cholinesterase inhibitor: a population-based study. Basic Clin Pharmacol Toxicol. 2019;124(6):741–8.

Article  CAS  PubMed  Google Scholar 

Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. J Alzheimers Dis. 2018;65(2):589–96.

Article  CAS  PubMed  Google Scholar 

Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs contributing to anticholine